De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans

Submitted by Anonymous on

Key Points Question Is early-onset severe generalized acanthosis nigricans (AN) associated with an increased risk of systemic disease? Findings In this case series study of 3 individuals with AN, using whole-exome sequencing (WES), recurrent de novo epidermal growth factor receptor...

EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge

Submitted by Anonymous on

Targeted therapies have revolutionized cancer care. Unfortunately, most patients develop refractory, multifocal resistance to these therapies within a matter of months. Here, we demonstrate that the evolution of resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer endows cells...

EGFR variant profiles in lung adenocarcinoma from different regions of Brazil: a multi-institutional study using a rapid RT‒PCR platform

Submitted by Anonymous on

AbstractBackground Lung adenocarcinoma frequently harbors activating EGFR variants, but their distribution may vary across Brazil due to regional demographic and ancestral differences. This study evaluated the frequency and subtype distribution of EGFR variants in three Brazilian regions and examined associations...

Phase 2 Trial Explores Osimertinib and Savolitinib Combination for NSCLC Patients with EGFR Mutations and MET Aberrations

Submitted by Anonymous on

Phase 2 Trial Explores Osimertinib and Savolitinib Combination for NSCLC Patients with EGFR Mutations and MET Aberrations A phase 2 clinical trial has provided new insights into potential treatments for non-small cell lung cancer (NSCLC) in patients with specific genetic...

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy

Submitted by Anonymous on

AbstractPurpose EGFR inhibitor (EGFRi) therapies have been FDA-approved for metastatic colorectal cancer (CRC). However, extended RAS/RAF testing required in the drug labels, identifies only non-responders, and only ~50% of selected patients respond to therapy, suggesting an unmet need to develop...

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Submitted by Anonymous on

Original Article Share on Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCAuthors: Pasi A. Jänne, M.D., Ph.D., David Planchard, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., James Chih-Hsin Yang, M.D., Ph.D., Ying Liu, M.D., Natalia Valdiviezo, M.D., Tae Min Kim,...

Correction to: Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis

Submitted by Anonymous on

Use our pre-submission checklist Avoid common mistakes on your manuscript. Correction to: Journal of Neuro-Oncology (2025) 174:471–482 https://doi.org/10.1007/s11060-025-05045-6 Figure 1 in this article included the following two errors: 1. The number specified for the “EGFR wild type” group was 216,...

Ultrasonication-assisted green synthesis, in silico EGFR-binding analysis, and cytotoxic evaluation of nitro-perimidines for non-small cell lung cancer

Submitted by Anonymous on

Abstract Three nitro-substituted 2,3-dihydro-1H-perimidine derivatives (ortho, meta-, and para-nitrophenyl) were synthesised via a novel, additive-free ultrasonication-assisted method with high yields (up to 90%). Their structures were validated experimentally and supported by DFT calculations, which also provided insight into the reaction...

Subscribe to Newsfeed